Table 1.
Baseline Characteristics of the Cohort
| Total Patients | 292 |
|---|---|
| PTH, pg/mL (normal range 15–65) | 49 (39–61) |
| Age, y | 61±11 |
| Hyperparathyroidism, No. (%) | 56 (19) |
| Primary hyperparathyroidism, No. (%) | 7 (2) |
| Females, No. (%) | 155 (53) |
| Smokers, No. (%) | 39 (13) |
| Diabetes mellitus, No. (%) | 59 (20) |
| Previous myocardial infarction, No. (%) | 21 (7) |
| Previous stroke, No. (%) | 18 (6) |
| Mean 24‐hour SBP, mm Hg | 128±12 |
| Mean 24‐hour DBP, mm Hg | 77±8 |
| Mean daytime SBP, mm Hg | 131±12 |
| Mean daytime DBP, mm Hg | 80±9 |
| Mean nocturnal SBP, mm Hg | 115±14 |
| Mean nocturnal DBP, mm Hg | 67±9 |
| BMI, kg/m2 | 29 (26–32) |
| LDL cholesterol, mg/dL | 117 (90–141) |
| Glycated hemoglobin, % | 5.7 (5.4–6.1) |
| eGFR, mL/min/m2 | 80±19 |
| eGFR <60 mL/min/m2, No. (%) | 41 (14) |
| eGFR <30 mL/min/m2, No. (%) | 3 (1) |
| Proteinuria, No. (%) | 22 (7) |
| 25(OH)D, ng/mL | 28 (21–36) |
| Albumin adjusted calcium, mmol/L | 2.39 (2.33–2.47) |
| Phosphate, mg/dL | 2.98±0.5 |
| NT‐proBNP, pg/mL | 85 (46–164) |
| Aldosterone, ng/dL | 16 (11–20) |
| Regular medication use, No. (%) | |
| β‐Blocker | 156 (53) |
| ACE inhibitor | 111 (38) |
| ARB | 81 (28) |
| Calcium antagonist | 75 (26) |
| MR blocker | 10 (3) |
| Loop diuretic | 11 (4) |
| Thiazide diuretic | 120 (41) |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate, calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula; LDL, low‐density lipoprotein; MR, mineralocorticoid receptor; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; PTH, parathyroid hormone; SBP, systolic blood pressure; 25(OH)D, 25‐hydroxy vitamin D3. Continuous variables are expressed as mean ±standard deviation in case of normal distribution and otherwise as median (interquartile range) and categorical variables as number (percentage).